SCHEMBL2344992

SCHEMBL2344992

Cc1cc(C2CC3(CCN(C(=O)Nc4onc(C)c4C)CC3)C2)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP2D6 P10635 3/20 0.40
CYP1A2 P05177 5/20 0.38
EPHX2 P34913 2/20 0.37
MGLL Q99685 3/20 0.37
TSHR P16473 2/20 0.36
ENPP2 Q13822 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
CYP2C19 P33261 2/20 0.35
CACNA1H O95180 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2346280 0.91 CYP3A4 (0.42) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2340195 0.91 P2RY1 (0.42) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2344406 0.89 EPHX2 (0.40) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2347247 0.86 ALDH1A1 (0.41) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2341595 0.85 CYP3A4 (0.42) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2348397 0.85 MGLL (0.49) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2343479 0.84 CYP3A4 (0.39) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2343534 0.84 CYP3A4 (0.39) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL13355105 0.84 CYP3A4 (0.43) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2
SCHEMBL2341906 0.84 CYP3A4 (0.44) CYP3A4ALDH1A1CYP2D6CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358704-A1 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase Pfizer Inc. (US) 2011-08-24 EP claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US claimed
WO-2010049841-A1 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE PFIZER INC. (US) 2010-05-06 WO claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS FAAH, FAAH2, APEH CYP3A4 912/4885ALDH1A1 739/4885CYP2D6 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.